International Accounting Standards Board

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Record, Safety, Annual general meeting, Cytokine release syndrome, Research, Type, Silicon Valley Bank, ASH, Non-Hodgkin lymphoma, CRS, International, Bank statement, Book, Silicon, Insurance, Patient, Genentech, FDA, Hodgkin lymphoma, Lung cancer, International Financial Reporting Standards, GVHD, Monroe Dunaway Anderson, International Accounting Standards Board, IASB, Cholangiocarcinoma, ORR, Roivant Sciences, Cancer, Trial of the century, Financial toxicity, Haematopoietic system, HL, EST, AML, Society, NHL, PTCL, NK, NSCLC, Cryptocurrency, Medical device, Vaccine, Pharmaceutical industry, Rare-earth element, Audit, Euro, Affimer

MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.

Key Points: 
  • MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the third quarter of 2023.
  • Total revenue for the quarter ended September 30, 2023, was €2.0 million compared with €14.9 million for the quarter ended September 30, 2022.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on November 14, 2023, at 8:30 a.m. EST / 14:30 CET to discuss third quarter 2023 financial results and corporate developments.

Gravity Reports Third Quarter of 2023 Results and Business Updates

Retrieved on: 
Monday, November 13, 2023
Online, Next Generation, Yoy, Federal Reserve Bank, Gravity, International, CBT, Ragnarök, Advertising, Quarter, Pepperstone, KRW, International Accounting Bulletin, International Accounting Standards Board, Ragnarok Online, International Financial Reporting Standards, Cryptocurrency, Video game, Food delivery, Hong Kong

Total revenues were KRW 176,145 million (US$ 130,685 thousand), representing a 26.3% decrease from the second quarter ended June 30, 2023 (“QoQ”) and a 72.1% increase from the third quarter ended September 30, 2022 (“YoY”).

Key Points: 
  • Total revenues were KRW 176,145 million (US$ 130,685 thousand), representing a 26.3% decrease from the second quarter ended June 30, 2023 (“QoQ”) and a 72.1% increase from the third quarter ended September 30, 2022 (“YoY”).
  • Online game revenues for the third quarter of 2023 were KRW 17,316 million (US$ 12,847 thousand), representing an 1.7% increase QoQ from KRW 17,025 million and a 10.1% decrease YoY from KRW 19,271 million.
  • Ragnarok Begins started its second CBT on November 1, 2023 and is preparing to be launched in South Korea in December 2023.
  • The presentation contains the Company’s recent business updates, results of the third quarter in 2023 and Gravity’s business plan.

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

Retrieved on: 
Monday, November 13, 2023
Defense, Health, FDA, Infectious Diseases, Pharmaceutical, Biotechnology, Contracts, NDA, Food and Drug Administration, Research, Bachelor of Science, Engineering, Food, Therapy, Infection, Technology transfer, Toxicology, Indian stock exchange, IND, Bank statement, Government, Patient, Strategic planning, Marketing, International Accounting Standards Board, New Drug Application, Investigational New Drug, USAFA, MBA, Partnership, CMC, TSX, Pharming, Drug development, Patent, Non-governmental organization, Pharmaceutical industry, Management, Cryptocurrency

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the second quarter of its fiscal year 2024, which ended on September 30, 2023.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the second quarter of its fiscal year 2024, which ended on September 30, 2023.
  • At Appili, we are proud of our strong government partnerships which enable us to advance this biodefense program towards an Investigational New Drug (“IND”).”
    The Company has made significant operational progress during this quarter.
  • Appili expects to receive additional milestone payments and royalties from its partner, Saptalis Pharmaceuticals (“Saptalis”) based on this FDA approval and Saptalis’ commercialization.
  • During our second fiscal quarter, Appili progressed early-stage development activities and regulatory activities.

Kindred Group plc - Interim report: January - September 2023 (unaudited), including non-recurring indicative underlying EBITDA guidance for the full year 2024

Retrieved on: 
Wednesday, November 29, 2023
EBITDA, ID, Disclosure, Kindred, Telephone, Sport, SEK, International Accounting Standards Board, Kindred Group, Growth, GBP, Auction, Arms industry, Commercial property

SLIEMA, Malta, Nov. 29, 2023 /PRNewswire/ --

Key Points: 
  • Underlying EBITDA increased by 6 per cent to GBP 42.6 (40.3) million.
  • Based on current market growth expectations, and considering Kindred's announced interim strategic review update, Kindred anticipates the full year 2024 underlying EBITDA to reach GBP 250 million.
  • Kindred also reiterates its full year 2023 underlying EBITDA guidance of at least GBP 200 million, assuming a normalised sports betting margin during the fourth quarter.
  • We reiterate our underlying EBITDA guidance for the full year 2023 of at least GBP 200 million, assuming a normalised sports betting margin during the fourth quarter."

Kindred Group plc - Interim report: January - September 2023 (unaudited), including non-recurring indicative underlying EBITDA guidance for the full year 2024

Retrieved on: 
Wednesday, November 29, 2023
EBITDA, ID, Disclosure, Kindred, Telephone, Sport, SEK, International Accounting Standards Board, Kindred Group, Growth, GBP, Auction, Arms industry, Commercial property

SLIEMA, Malta, Nov. 29, 2023 /PRNewswire/ --

Key Points: 
  • Underlying EBITDA increased by 6 per cent to GBP 42.6 (40.3) million.
  • Based on current market growth expectations, and considering Kindred's announced interim strategic review update, Kindred anticipates the full year 2024 underlying EBITDA to reach GBP 250 million.
  • Kindred also reiterates its full year 2023 underlying EBITDA guidance of at least GBP 200 million, assuming a normalised sports betting margin during the fourth quarter.
  • We reiterate our underlying EBITDA guidance for the full year 2023 of at least GBP 200 million, assuming a normalised sports betting margin during the fourth quarter."

Perimeter Medical Imaging AI Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
FSE, ID, Protocol, International, Surgeon, Clinical trial, IAS, FDA, Marketing, ARPA, International Accounting Standards Committee, International Accounting Standards Board, PINK, Perimeter, University, Software, Mayo Clinic, AI, Physician, OTC, DARPA, International Financial Reporting Standards, Rare-earth element, Medical device, Management, Cryptocurrency, DALLAS, Health

TORONTO and DALLAS, Nov. 14, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today reported financial results for its third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • TORONTO and DALLAS, Nov. 14, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today reported financial results for its third quarter ended September 30, 2023 and provided a corporate update.
  • Based on feedback from the FDA, we successfully introduced improved AI into the ongoing clinical trial evaluating the use of Perimeter B-Series OCT combined with AI during breast conservation surgery.
  • Many physicians support our belief that combining AI with high-resolution imaging has the potential to become a new standard of care during breast conservation surgery."
  • The Company will host a conference call and live audio webcast today at 5:00 pm Eastern Time to discuss its third quarter 2023 results and to provide a corporate update.

Helios Fairfax Partners Reports Third Quarter Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Sale, AGH, International Accounting Standards Committee, Sport, International, FOR, Urbanization, News, Insurance, HFP, Investment, NOT, Bank statement, International Accounting Standards Board, TSX, Life insurance, Bank

TORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Helios Fairfax Partners Corporation (TSX: HFPC.U) today announced its financial results for the three and nine months ended September 30, 2023. All dollar amounts in this news release are expressed in U.S. dollars except as otherwise noted. The financial results are derived from the interim consolidated financial statements prepared using the recognition and measurement requirements of International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), except as otherwise noted.

Key Points: 
  • NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
    TORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Helios Fairfax Partners Corporation (TSX: HFPC.U) today announced its financial results for the three and nine months ended September 30, 2023.
  • The financial results are derived from the interim consolidated financial statements prepared using the recognition and measurement requirements of International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), except as otherwise noted.
  • We have also entered into an agreement to sell certain other related Legacy Non-Core Investments which are expected to be completed through 2024,” said Tope Lawani and Babatunde Soyoye, Co-CEO’s of Helios Fairfax Partners.
  • HFP reported a book value per share of $5.11 as of September 30, 2023, as compared to $5.13 in the prior quarter.

Fairfax India Holdings Corporation: Third Quarter Financial Results

Retrieved on: 
Thursday, November 2, 2023
Fairfax Financial, International Accounting Standards Committee, WIRE, International, Tax, FOR, Investment, NEWS, Legislation, NOT, Bank statement, NSE, CSB Bank, International Accounting Standards Board, TSX, Security (finance), Cryptocurrency

TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Fairfax India Holdings Corporation (TSX: FIH.U) announces net earnings of $133.0 million in the third quarter of 2023 ($0.93 net earnings per diluted share), compared to net earnings of $112.6 million in the third quarter of 2022 ($0.79 net earnings per diluted share).

Key Points: 
  • The financial results are derived from financial statements prepared using the recognition and measurement requirements of International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), except as otherwise noted, and are unaudited.
  • TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Fairfax India Holdings Corporation (TSX: FIH.U) announces net earnings of $133.0 million in the third quarter of 2023 ($0.93 net earnings per diluted share), compared to net earnings of $112.6 million in the third quarter of 2022 ($0.79 net earnings per diluted share).
  • The company recorded a performance fee of $20.5 million for the third quarter of 2023 and at September 30, 2023 had accrued $82.6 million to the benefit of Fairfax Financial Holdings.
  • Fairfax India is in strong financial health, with cash and marketable securities of approximately $261 million.

Algoma Steel Group Reports Fiscal Second Quarter 2024 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Adjustment, Ontario government debt, Strategic Innovation Fund, International Accounting Standards Board, EDT, International, Earnout, EDGAR, Algoma Steel, EBITDA, Legislation, News, Carbon, Conference, Maintenance, UAW, Bank statement, Nature, ASTL, EAF, Webcast, Corporation, Hand, Steel, MSCI EAFE, Calendar, TSX, STE, Blast furnace, Video game, Holding company, Audit, Counsel

SAULT STE. MARIE, Ontario, Nov. 02, 2023 (GLOBE NEWSWIRE) --  (November 2, 2023) – Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or “the Company”), a leading Canadian producer of hot and cold rolled steel sheet and plate products, today announced results for its fiscal second quarter ended September 30, 2023.

Key Points: 
  • MARIE, Ontario, Nov. 02, 2023 (GLOBE NEWSWIRE) --  (November 2, 2023) – Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or “the Company”), a leading Canadian producer of hot and cold rolled steel sheet and plate products, today announced results for its fiscal second quarter ended September 30, 2023.
  • Michael Garcia, the Company’s Chief Executive Officer, commented, “We delivered results in the fiscal second quarter that were in line with our previously disclosed outlook.
  • Net income in the second quarter was $31.1 million, compared to net income of $87.2 million in the prior-year quarter.
  • Upon dialing in, please request to join the Algoma Steel Second Quarter Conference Call.

Profound Medical Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Sale, International Accounting Standards Committee, Temperature, Food, International, PIN, United States Army Medical Corps, G&A, Telephone, Workforce, International Financial Reporting Standards, Maintenance, Research, Engineering, S&D, Software, Bank statement, Clinical trial, Surgeon, Interim, Webcast, Consultant, Patient, International Accounting Standards Board, TSX, Pharmaceutical industry, Video game, Cryptocurrency

TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2023.
  • Third quarter 2023 S&D expenses were approximately $2.2 million, down less than 1% from the third quarter of 2022.
  • For complete financial results, please see Profound’s filings at www.sedarplus.ca , www.sec.gov and on the Company’s website at www.profoundmedical.com under “Financial” in the Investors section.
  • Profound Medical is pleased to invite all interested parties to participate in a conference call today at 4:30 pm ET during which time the results will be discussed.